Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity.
Chabner
B A
BA
Laboratory of Chemical Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20014, USA.
Johns
D G
DG
Bertino
J R
JR
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy / Q000517:prevention & control*; D006207:Half-Life; D006868:Hydrolysis; D002955:Leucovorin / Q000493:pharmacokinetics / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000009:adverse effects* / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use; D051379:Mice; D011549:Pseudomonas / Q000201:enzymology*; D015996:Survival Rate; D013997:Time Factors; D015431:Weight Loss / Q000187:drug effects; D011623:gamma-Glutamyl Hydrolase / Q000008:administration & dosage / Q000378:metabolism* / Q000493:pharmacokinetics / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011623:gamma-Glutamyl Hydrolase; D002955:Leucovorin; D008727:Methotrexate